ASA: Perioperative Bleeding and Aspirin Use in Spine Surgery

Sponsor
University Hospitals Cleveland Medical Center (Other)
Overall Status
Withdrawn
CT.gov ID
NCT02807441
Collaborator
(none)
0
1
3
41
0

Study Details

Study Description

Brief Summary

The investigators would like to further the current understanding of aspirin and its effects on perioperative bleeding by conducting a randomized controlled trial of spinal surgery patients receiving varying doses of aspirin or no aspirin perioperatively. The investigators hypothesize that there will be no significant difference in perioperative blood loss between the different groups.

Condition or Disease Intervention/Treatment Phase
  • Drug: Acetylsalicylic acid
Phase 3

Detailed Description

Selected patients will be given either no aspirin, low-dose aspirin (81 mg), or high-dose aspirin (325 mg) in the perioperative period. These dosages are based on the Pharmacist's letter/Prescriber's letter which provides aspirin dosing recommendations for varying cardiovascular indications. Allocation of dosing will be based on computerized randomization in order to achieve approximately 100 patients in each group. Patient records will then be assessed for demographic characteristics, comorbidities, symptoms, functional outcome scores (Sf-12), operative time, intraoperative estimated blood loss, postoperative blood loss in drainage tubes (when applicable), cumulative blood loss, transfusion of blood products, hemoglobin level, preoperative International Normalized Ratio (INR), preoperative platelet count, hospital length of stay, and morbidity and mortality including development of NSTEMI, atrial fibrillation, surgical site infection, pulmonary embolism, and hospital 30-day readmission rates.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Association Between Perioperative Bleeding and Aspirin Use in Spine Surgery: A Randomized, Controlled Trial
Study Start Date :
Jul 1, 2016
Anticipated Primary Completion Date :
Jul 1, 2019
Anticipated Study Completion Date :
Dec 1, 2019

Arms and Interventions

Arm Intervention/Treatment
No Intervention: No aspirin

Patients will not be given any Acetylsalicylic acid in the perioperative period.

Experimental: Low-dose aspirin

Patients will be given low-dose Acetylsalicylic acid (81 mg) in the perioperative period.

Drug: Acetylsalicylic acid
Patients will receive different doses of aspirin perioperatively to assess bleeding association.
Other Names:
  • aspirin
  • Experimental: High-dose aspirin

    Patients will be given high-dose Acetylsalicylic acid (325 mg) in the perioperative period.

    Drug: Acetylsalicylic acid
    Patients will receive different doses of aspirin perioperatively to assess bleeding association.
    Other Names:
  • aspirin
  • Outcome Measures

    Primary Outcome Measures

    1. Hemorrhage: Amount of blood loss [Intraoperative]

      Amount of blood loss from the operation will be recorded

    2. Hemorrhage: Amount of blood loss [48 hours Postoperative]

      Blood loss from drainage tube when applicable

    Secondary Outcome Measures

    1. Blood Transfusion: Amount of blood products transfused [Intraoperative]

      Amount of blood products transfused when applicable

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • All patients over 18 years old, who are not taking aspirin at the time of operation as part of a current cardiovascular treatment plan, who will undergo spinal surgery from 2016-2019 in the practice of Dr. Eubanks.
    Exclusion Criteria:
    • Any patient under the age of 18 and/or is already taking anticoagulant therapy for an established cardiovascular disease at the time of surgery as part of a cardiovascular therapy.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Hospitals Case Medical Center Cleveland Ohio United States 44106

    Sponsors and Collaborators

    • University Hospitals Cleveland Medical Center

    Investigators

    • Principal Investigator: Jason Eubanks, MD, University Hospitals Cleveland Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Heather Fuhrman, medical student, University Hospitals Cleveland Medical Center
    ClinicalTrials.gov Identifier:
    NCT02807441
    Other Study ID Numbers:
    • UHCMC-Ortho
    First Posted:
    Jun 21, 2016
    Last Update Posted:
    Oct 11, 2021
    Last Verified:
    Oct 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by Heather Fuhrman, medical student, University Hospitals Cleveland Medical Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 11, 2021